Mini Review of Prostate Cancer Diagnostics_ Crimson Publishers

 Mini Review of Prostate Cancer Diagnostics by Besarion Partsvania* in Novel Approaches in Cancer Study_ Journal of Cancer Research

 

Abstract
According to the World Health Organization (WHO) prostate cancer is the second cause of cancer death in men worldwide [1,2]. Some advanced prostate cancers have well known symptoms. However non-cancerous diseases of the prostate, such as benign prostatic hyperplasia (BPH) cause same symptoms. On the other hand, at very early stages, prostate cancer has no symptoms, the tumor dimension is quite small, and it is extremely difficult to detect it. If prostate cancer is detected at an early stage, it can be successfully cured by different methods. At the later stages, treatment or surgery has very low efficiency. Prostate cancer can often be found by measuring the amount of PSA in the blood. Most healthy men have levels under 4 nano-grams per milliliter (ng/mL) of blood. When prostate cancer develops, the PSA level usually goes above 4. However, for determination of the existence of cancer, some additional methods are used: for example: PSA velocity [3,4] and/or PSA density. Besides, measurement of the ratio of free to total PSA is additional tool in prostate cancer diagnosis [5]. However, the major drawback of PSA determination is its relative lack of specificity. The PSA level can also be increased by benign prostate hyperplasia (BPH) - a noncancerous enlargement of the prostate, prostatitis, etc.

Digital rectal examination (DRE) is one of methods for prostate cancer diagnosis. The vast majority of prostatic carcinomas arise in the peripheral zone of the prostate. This part of the gland is accessible by DRE [6,7]. The DRE screening test for prostate cancer requires to assess the size, shape, and texture of the prostate and nearby organs. The sensitivity and specificity of a DRE examination is subject to a physician’s skill, the clinician’s ability to interpret what is felt, and the nature of the patient’s disease. Although DRE can detect prostate cancer, it has limited sensitivity. Unfortunately, many cancers detected using DRE are either locally or regionally advanced. Prostate cancer may be identified on Trans-rectal ultrasound (TRUS) as a hypoechoic lesion. However, only 60% of prostate cancers appear hypoechoic on ultrasound while most of the remaining cancers appear isoechoic with respect to the surrounding parenchyma [8]. Because other disease processes, such as BPH and prostatitis may have a similar appearance to prostate cancer, it is impossible to reliably differentiate these lesions from prostate cancer based on ultrasonographic characteristics alone. Consequently, TRUS should not be used as a first line screening study as it lacks acceptable specificity

https://crimsonpublishers.com/nacs/fulltext/NACS.000573.php

Crimson Publishers: https://crimsonpublishers.com/

For more articles in Journal of Cancer Research,
Please click on below link: https://crimsonpublishers.com/nacs/